You are here

Share:

Search Technologies

Showing 1-20 of 36 results found

3D Image Rendering Softwarefor Biological Tissues

The Frederick National Laboratory for Cancer Research seeks parties interested in collaborative research to co-develop software for the automatic 3-D visualization of biological image volumes.

A Mobile Health Platform

Researchers at the National Institute on Drug Abuse (NIDA) seek licensing or co-development of a mobile health technology that monitors and predicts a user’s psychological status in order to deliver an automated intervention when needed.

Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof

The technology is a series of modafinil analogues that bind with moderate to high affinity to the dopamine (DA) transporter (DAT). Some compounds also have affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. The compounds retain the desired dopamine transporter affinity with greater metabolic stability over previously described unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment. Researchers at the National Institute on Drug Abuse (NIDA) seek licensing and/or co-development research collaborations for further development and commercialization of the compounds.

Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2

Recombinant human tissue inhibitors of metalloproteinases (rhTIMP-2) have been shown to suppress tumor growth and tumor-associated angiogenesis. NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line which stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.

Device for Simulating Explosive Blast and Imaging Biological Specimens

Researchers at the National Institute of Child Health and Human Development (NICHD) developed a device simulating a blast shock wave of the type produced by explosive devices such as bombs. The invention allows for the real-time study of blast effects on in vitro cell models. NICHD researchers seek licensing opportunities to further develop this device.

Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel

Hibernation in mammals is a seasonal state of metabolic suppression and dormancy characterized by a decrease in body temperature to survive extreme environmental stresses. A new Induced Pluripotent Stem Cell (iPSC) line has been established from the neural precursor cells of wild type thirteen-lined ground squirrel (Spermophilus tridecemlineatus), a small mammalian hibernator with unique metabolic adaptations for coping with cold and restricted food supply. This ground squirrel iPSC line can be differentiated into many different cell types for hibernation studies, disease modeling, and drug screening for neuronal injuries or other diseases.

Genetic Assay for Transcription Errors: Methods to Monitor Treatments or Chemicals that Increase the Error Rate of RNA synthesis

Researchers at the National Cancer Institute (NCI) developed a genetic assay for detecting transcription errors in RNA synthesis. This new assay extends the familiar concept of an Ames test which monitors DNA damage and synthesis errors to the previously inaccessible issue of RNA synthesis fidelity. The FDA requires genetic DNA focused tests for all drug approval as it assesses the in vivo mutagenic and carcinogenic potential of a drug. The new assay will open an approach to monitoring the impact of treatments on the accuracy of RNA synthesis. Errors in transcription have been hypothesized to be a component of aging and age-related diseases. The National Cancer Institute (NCI) seeks licensing partners for the genetic assay.

Human Research Information System (HuRIS)

Researchers at the National Institute on Drug Abuse (NIDA) seek licensing or co-development of a Human Research Information System (HuRIS) software that automates all major functions of a clinical-research entity. The system is designed for commercial healthcare providers, community treatment centers, and clinical research facilities.

Isotropic Generalized Diffusion Tensor MRI

The Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) seeks research and co-development partners or licensees for an invention that discloses the diagnosis of pathologies in tissue related to changes in cell size, cellularity, cell infiltration, and other abnormalities detected by bulk water diffusion changes.

Ketamine Metabolites for the Treatment of Depression and Pain

The National Institute on Aging, Laboratory of Clinical Investigation, is seeking parties interested in collaborative research to co-develop ketamine metabolites for the treatment of different forms of depression and for alleviating pain.

MADCO-Accelerated Multidimensional Diffusion MRI

The marginal distribution constrained optimization (MADCO) methodology is disclosed wherein a 2D (or higher-dimensional) spectrum is estimated from initial 1D marginal distribution data. These 1D marginal distributions are used as constraints in the reconstruction of the 2D spectra. MADCO accelerates and improves the reconstruction of multidimensional NMR relaxation/diffusion spectra, making it suitable for MRI applications on a voxel-by-voxel basis by vastly reducing the amount of data acquired and data necessary for creating MRI images.

Method and Device for Selectively Labeling RNA

The National Cancer Institute's Structure Biophysics Lab seeks partners interested in licensing or co-developing a technology to site-specifically label RNA.

Methods and Compositions for Treating Lysosomal Storage Diseases

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking a co-development partner or licensee to advance its recombinant adeno-associated virus- (AAV-)based gene therapy for Alpha-mannosidosis, a prototypical lysosomal storage disease.

Methods of Treating or Preventing Demyelation Using Thrombin Inhibitors

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (“NICHD”), seek CRADA partner or collaboration for development of agents to treat multiple sclerosis or other conditions associated with myelin remodeling by administering an agent that inhibits cleavage of Neurofascin 155 or Caspr1. The agent could be a thrombin inhibitor, an agent that inhibits thrombin expression, an anti-thrombin antibody that specifically inhibits thrombin mediated cleavage of Neurofascin 155, a mutated version or fragment of Neurofascin 155 or Caspr1, or antibodies to Neurofascin 155 or Caspr1.

Micro-Dose Calibrator for Pre-clinical Radiotracer Assays

Pre-clinical radiotracer biomedical research involves the use of compounds labeled with radioisotopes, including cell binding studies, immune cell labeling techniques, and radio-ligand bio-distribution studies. Before this Micro-Dose Calibrator, measurement of pre-clinical level dosage for small animal studies was inaccurate and unreliable. This dose calibrator is a prototype ready for manufacturing. It is designed to accurately measure radioactive doses in the range of 50 nCi (1.8 kBq) to 100 µCi (3.7 MBq) with 1% precision. The NCI seeks co-development or licensing to commercialize it. Alternative uses will be considered.

Pages